Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Company Summary - Heng Rui Medicine and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. have announced the approval for clinical trials of HRS-4729 injection [1] - HRS-4729 is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which is expected to enhance energy expenditure and lipid metabolism compared to dual-target therapies [1] Industry Summary - The drug is positioned to better regulate glucose and lipid metabolism, suppress appetite, and promote fat oxidation, potentially offering improved weight loss and liver fat reduction effects [1]